Lytix Biopharma AS
SWB:6BG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Lytix Biopharma AS (6BG) under the Base Case is 12.9 EUR per share. Compared with the current market price of 38.5 EUR, the stock appears Overvalued by 67% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Lytix Biopharma AS Does
Lytix Biopharma AS is a Norwegian biotechnology company that develops cancer medicines based on the body’s own immune system. Its core idea is to make tumor cells easier for the immune system to recognize and attack, rather than relying only on traditional chemotherapy or surgery. The company’s work centers on drug candidates designed for use in oncology, especially in tumors that are hard to treat with standard approaches.
- Headquarters
- Norway NO
- Employees
- 14
- IPO date
- Jun 14, 2021
Earnings Waterfall
Lytix Biopharma AS
What is the Intrinsic Value of one 6BG stock?
The intrinsic value for Lytix Biopharma AS (6BG) under the Base Case is 12.9 EUR.
Is 6BG stock undervalued or overvalued?
Compared with the current market price of 38.5 EUR, the stock appears Overvalued by 67% .